News Archive

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore (UMB) for a novel drug delivery platform, Nano-Polymer-Drug Conjugate Systems (NPDCS). This technology targets the delivery of currently marketed chemotherapeutic agents directly into cancerous tumors. The direct delivery of chemotherapeutic drugs into the tumors has been shown to result in increased efficacy and reduced toxicity.

The NPDCS platform combines existing chemotherapeutic agents with a proprietary polymer carrier that contains a signaling moiety which directs the drug into the tumor. This approach minimizes the levels of freely circulating anti-cancer agents in the body, which can dramatically reduce potential adverse events, and maximizes anti-tumor activity by accumulating in the cancer tumor. NPDCS is a broad platform that has the potential to generate multiple therapeutic candidates going forward.

Summer wouldn’t be complete without a trip to the sandy shores of an ocean, bay, lake or river. As the gritty stuff gets in between your toes, you may wonder why beaches are distinctive sandy stretches and why sand looks and feels the way it does.

And then again, you might not — you didn’t come to the beach to think, did you? But for those in an asking mood, a sandy beach is essentially where pulverized, weathered rock along with some fragments of shelled creatures and other biota have collected, tossed up by the waves and as sediment from inland areas.

National Cancer Institute scientists have released the largest-ever database of cancer-related genetic variations, providing researchers the most comprehensive way so far to figure out how to target treatments for the disease.

Open access worldwide to the new database, based on genome studies, is expected to help researchers accelerate development of new drugs and better match patients with therapies, NCI said in a statement on Monday.

Here’s another reason the dysfunctional federal budget process is bad for Americans: besides hurting the economy and hitting us in the pocketbook, partisan feuding over budget cuts could undermine our health and even shorten our lives.

That’s because House Majority Leader Eric Cantor and others in Congress have been using the budget process to target research in the behavioral and social sciences for elimination, even though they’re indispensable to understanding and improving Americans’ health.

A Silver Spring company is looking to build the county’s first net zero facility, a building that would produce enough energy to sustain itself annually.

United Therapeutics —a biotechnology company that works on the development and commercialization of unique medical products — is expanding its campus with the new facility on the corner of Spring Street and Colesville Road in downtown Silver Spring. The building at 1000 Spring Street will have solar panels, a green roof and special placement of windows to allow for natural light and cross breezes to push hot air out of the facility, among other environmentally sustainable features, according to a presentation the design team gave to the Silver Spring Citizens Advisory Board on July 8.

The Maryland Industrial Partnerships (MIPS) program, an initiative of the Maryland Technology Enterprise Institute (Mtech) in the A. James Clark School of Engineering at the University of Maryland, has awarded $3.8 million to 17 teams combining Maryland companies with university researchers to bring technology products closer to market, program officials announce today.

MIPS, a technology acceleration program, grants money matched with company funds to faculty engaged in each project.

Johns Hopkins Hospital has reclaimed the top position on U.S. News & World Report’s 2013-2014 list of best hospitals.

The return to No. 1 comes a year after Massachusetts General Hospital edged out Hopkins for the top spot on last year’s honor roll list. Hopkins had been No. 1 since 1991.

Renee M. Winsky of Davidsonville has been named president and CEO of Leadership Maryland, a statewide leadership development program.

She replaces Nancy Minieri, who founded the organization in 1992. Minieri announced in March that she will retire at the end of this year.

Winsky is a 2005 graduate of Leadership Maryland. In the yearlong program, participants learn about problems and opportunities facing the state. More than 900 people have taken the course, including elected officials, business executives, educators and nonprofit directors.

Topic:   “EIRs, SBIRs, and more with BioHealth Innovation, Inc.”

Presenters:

• Richard Bendis, President and CEO
• Ethan Byler, Director, Innovation Programs
• Todd Chappell, Entrepreneur-in-Residence, NIH-OTT
• Dr. Ken Malone, Entrepreneur-in-Residence, UMD Ventures
• Ram Aiyar, Entrepreneur-in-Residence, NHLBI

BioHealth Innovation, Inc. (BHI) is a regional innovation intermediary that accelerates and facilitates technology transfer and commercialization of market-relevant research in federal labs, universities, and biohealth companies in the Region. It is a private-public partnership that connects the Region’s innovation assets to provide integrated technical knowledge, financial means, and entrepreneurial/managerial expertise to turn promise into prosperity for the region while advancing human health.

BHI’s Entrepreneur-in-Residence (EIR) program is designed to be an active partner with research institutions to source, fund, and grow high-potential, early-stage products through project-focused companies. The entrepreneurs in the program support the formation of new companies based upon innovative discoveries in the areas of drugs, vaccines, therapeutics, diagnostics, and medical devices from the intramural research programs at the NIH and Food and Drug Administration (FDA), as well as from universities and businesses.

BHI’s Commercial Relevance Program (CRP) offers biohealth companies support in preparing applications for federal funding inclusive of SBIRs, STTRs, and other federal government awards. Companies submit their federal funding concepts and receive pre-proposal feedback to help troubleshoot and strengthen your application. Further support from professional consultants and service providers is available to assist in improving your application.

BHI recently published the Central Maryland BioHealth Entrepreneur’s Resource and Finance Guide 2013. The Guide serves as a compendium of resources to biohealth innovators and entrepreneurs working to start and grow new companies and technologies in the region.

The Partnering Agreements with United Therapeutics 2005-2013 report provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies.

This report provides all the information you require to better understand United Therapeutics and its partnering interests and activities over the past seven years.

On demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data.